Today it’s Friday 13th and we’re heading off on the road again, this time to Washington DC for the much anticipated annual meeting of the American Urology Association (AUA).
We’ll be covering the hot topics on urologic cancers, including bladder and prostate cancers and renal cell carcinoma (RCC). I’m particularly interested in castrate resistant prostate cancer and updates on the abiraterone (Zytiga) data following the recent approval post chemotherapy in the US, and also the long term data for Medivation/Astellas’ MDV3100 from their phase I/II trial. It’s always important to know how patients in the early trials are doing.
We will post various updates here on Pharma Strategy Blog over the weekend including blog posts, podcasts and of course, video highlights. Do check back daily for news and snippets about what’s hot here at AUA.
In the meantime, you can also follow the aggregated tweets from the attendees – if you have a question, please don’t hesitate to ask me on Twitter (@maverickny) using the offical conference hashtag #aua2011 or in the blog comments below: